Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362898 | 0.90 | RXFP1 (0.46) | RXFP1EGLN1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL6631743 | 0.89 | RXFP1 (0.43) | RXFP1SMN1; SMN2CYP1A2CYP2C9HPGD | |
| SCHEMBL7646442 | 0.84 | SMN1; SMN2 (0.43) | RXFP1EGLN1SMN1; SMN2NR3C1POLA1 | |
| SCHEMBL6288607 | 0.83 | POLA1 (0.44) | EGLN1CYP1A2HPGDCYP2C19POLA1 | |
| SCHEMBL6706694 | 0.82 | SMN1; SMN2 (0.48) | RXFP1EGLN1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL6710728 | 0.82 | EGLN1 (0.47) | RXFP1EGLN1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL6199043 | 0.81 | EGLN1 (0.45) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6199600 | 0.81 | EGLN1 (0.45) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6707995 | 0.80 | KCNH2 (0.61) | RXFP1POLA1 | |
| SCHEMBL6706460 | 0.80 | SMN1; SMN2 (0.43) | EGLN1SMN1; SMN2CYP1A2CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102473-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W (US) | 2004-05-27 | — | — | US | claimed |
| JP-2002539130-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1159279-B1 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2002-10-16 | — | — | EP | claimed |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | claimed |
| EP-1159279-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-05 | — | — | EP | claimed |
| US-6239142-B1 | HERPES VIRUS INFECTION | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | claimed |
| WO-2000053610-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-14 | — | — | WO | claimed |
| US-20040102473-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W (US) | 2004-05-27 | — | — | US | disclosed |
| US-6495683-B2 | HERPES VIRUS | PHARMACIA AND UPJOHN COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1159279-B1 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | disclosed |
| EP-1159279-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6239142-B1 | HERPES VIRUS INFECTION | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2000053610-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102473-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, TGFB1 | RXFP1 135/4885EGLN1 1710/4885SMN1; SMN2 3446/4885 |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | IRF3, IL4, ZC3HAV1 | RXFP1 2912/4885EGLN1 2172/4885SMN1; SMN2 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.